Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03209791 · ClinicalTrials.gov registry record
Ethanol Induces Skeletal Muscle Autophagy
A clinical trial of Alcoholic Liver Disease, sponsored by The Cleveland Clinic.
- Recruiting
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT03209791: Recruiting study of Alcoholic Liver Disease, sponsored by The Cleveland Clinic.
NCT03209791 is a study of Alcoholic Liver Disease that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 40 participants, below the 69-participant average among 5 other Alcoholic Liver Disease trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03209791, a study of Alcoholic Liver Disease, is actively recruiting participants, sponsored by The Cleveland Clinic.
- RECRUITING
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study we plan to demonstrate that ethanol induces skeletal muscle autophagy to degrade MAA adducts.
Primary Outcome
We will measure Malonyldialdehyde Acetaldehyde protein adducts to see skeletal muscle proteolysis during a one time muscle biopsy
Conditions Studied
Interventions
- OTHER Biopsies
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-05-18 |
| Est. Completion | 2027-12-31 |
What NCT03209791 shows while recruiting
NCT03209791 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 69-participant average among 5 other Alcoholic Liver Disease trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Alcoholic Liver Disease appearing as the primary indexed condition, and to 1 intervention - of which Biopsies is the first listed.
NCT03209791 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT03209791 about?
NCT03209791 is a clinical study titled "Ethanol Induces Skeletal Muscle Autophagy". In this study we plan to demonstrate that ethanol induces skeletal muscle autophagy to degrade MAA adducts.
What is the current status of trial NCT03209791?
This trial is currently recruiting. The enrollment target is 40 participants. The study started on 2015-05-18. Estimated completion is 2027-12-31.
What conditions does trial NCT03209791 study?
This clinical trial studies the following conditions: Alcoholic Liver Disease.
What interventions are being tested in trial NCT03209791?
The interventions under investigation include: Biopsies (OTHER).
Who is sponsoring clinical trial NCT03209791?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03209791 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholic Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19
RECRUITING · NA
-
Evaluating Alcohol Use in Alcoholic Liver Disease
RECRUITING
-
Quantitative MRI for Non-invasive Assessment of Severity of Alcoholic Liver Disease (ALD)
ACTIVE NOT RECRUITING
-
Alcoholic Liver Disease and the Gut Microbiome
ACTIVE NOT RECRUITING · NA
-
A Novel Pharmacotherapy for Alcoholism and Alcohol Liver Disease
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI